Inovio Pharmaceuticals (NASDAQ:INO), According to the latest information the short interest in Inovio Pharmaceuticals, Inc. shot up by 2.4% or 270,348 shares. The final shorts are 16.7% of the total floated shares. The positions increased from 11,082,589 shares on May 31,2016 to 11,352,937 on June 15,2016. According to the per-day average trading of 1,392,260 shares, the days to cover are 8. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $9.11 on Friday but the bulls could not build on the opening and the stock topped out at $9.49 for the day. The stock traded down to $9.03 during the day, due to lack of any buying support eventually closed down at $9.17 with a loss of -6.90% for the day. The stock had closed at $9.85 on the previous day. The total traded volume was 2,744,479 shares.
The company shares have rallied 14.77% from its 1 Year high price. On Apr 28, 2016, the shares registered one year high at $11.69 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $10.45 and the 200 Day Moving Average price is recorded at $8.11.
Inovio Pharmaceuticals (NASDAQ:INO) has tumbled 12.42% during the past week and has dropped 13.57% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 10.96%. Inovio Pharmaceuticals (NASDAQ:INO) has underperformed the index by 10.96% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.